Passage BIO, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PASG$3.78+10.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · (Unaudited) · · · | ||||||
| (in thousands, except share and per share data) · · September 30, 2026 · · December 31, 2025 | ||||||
| Assets · · · · | ||||||
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $20,160 | | $46,303 | ||
| Prepaid expenses and other current assets | | 517 | | 629 | ||
| Prepaid research and development | | 116 | | 830 | ||
| Total current assets | | 20,793 | | 47,762 | ||
| Property and equipment, net | | — | | 4,107 | ||
| Right of use assets - operating leases | | | — | | 10,168 | |
| Other assets | | — | | 244 | ||
| Total assets | | $20,793 | | $62,281 | ||
| Liabilities and stockholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $533 | | $1,113 | ||
| Accrued expenses and other current liabilities | | 3,183 | | 4,653 | ||
| Non-refundable sublicense and transition services payments | | | 17,027 | | | 13,750 |
| Operating lease liabilities | | | — | | 3,567 | |
| Total current liabilities | | 20,743 | | 23,083 | ||
| Operating lease liabilities - noncurrent | | — | | 20,443 | ||
| Total liabilities | | 20,743 | | 43,526 | ||
| | | | | | | |
| Commitments and contingencies (note 10) | | | | | ||
| | | | | | | |
| Stockholders’ equity: | | | | | ||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both September 30, 2026 and December 31, 2025 | | | — | | | — |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 3,217,810 shares issued and outstanding at September 30, 2026 and 3,182,810 shares issued and outstanding at December 31, 2025 | | — | | — | ||
| Additional paid‑in capital | | 724,906 | | 723,512 | ||
| Accumulated deficit | | (724,856) | | (704,757) | ||
| Total stockholders’ equity | | 50 | | 18,755 | ||
| Total liabilities and stockholders’ equity | | $20,793 | | $62,281 | ||
See accompanying notes to unaudited interim consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.